Table 1.
Clinicopathologic characteristics of the SLE patients from discovery cohort.
| Discovery cohort | SLE_A (n = 48) | SLE_I (n = 82) | |
|---|---|---|---|
| Age, (mean ± SD) | 37 ± 13 | 40 ± 12 | |
| Sex, Female (%) | 40 (83.3) | 70 (85.3) | |
| Clinical Criteria | |||
| Rash (%) | 14 (29.2) | 18 (22.0) | |
| Oral ulcers (%) | 3 (6.3) | 0 | |
| Nonscarring alopecia (%) | 3 (6.3) | 2 (2.4) | |
| Fever (%) | 14 (29.2) | 4 (4.9) | |
| Serositis (%) | 2 (4.2) | 3 (3.7) | |
| Synovitis involving two or more joints (%) | 19 (39.6) | 8 (9.8) | |
| Renal disorder (%) | 32 (66.7) | 14 (17.1) | |
| Neurologic disorder (%) | 0 | 0 | |
| Leukopenia (< 3000/mm3, (%)) | 4 (8.3) | 7 (8.5) | |
| Thrombocytopenia (<100,000/mm3, (%)) | 6 (12.5) | 2 (2.4) | |
| LAC, (mean ± SD) | 1.2 ± 0.2 | 1.3 ± 0.3 | |
| APTT, (sec, mean ± SD) | 33.6 ± 10.4 | 30.9 ± 8.0 | |
| PT, (sec, mean ± SD) | 12.0 ± 1.3 | 12.1 ± 1.7 | |
| ESR, (mm/h, mean ± SD) | 40.3 ± 28.9 | 32.8 ± 29.1 | |
| CRP, (mg/L, mean ± SD) | 9.0 ± 15.7 | 8.4 ± 17.8 | |
| Immunological Criteria | |||
| Positive ANA (%) | 42 (87.5) | 66 (80.5) | |
| Anti-dsDNA (%) | 31 (64.6) | 26 (31.7) | |
| Anti-β2GPI, (AU/ml, mean (range)) | 8.5 (2.0-81.0) | 11.5 (2.0-200.0) | |
| ACL-IgG, (GPLU/ml, mean (range)) | 11 (1.7-120.0) | 11.8 (1.0-200.0) | |
| ACL-IgM, (MPLU/ml, mean (range)) | 4.6 (2.0-41.5) | 2.9 (2.0-12.6) | |
| Low complement 3 (low C3) (%) | 29 (60.4) | 22 (26.8) | |
| Low complement 4 (low C4) (%) | 22 (45.8) | 25 (30.5) | |
| Current drug use | |||
| Prednison (%) | 20 (41.7) | 39 (47.6) | |
| Methylprednisolone (%) | 24 (50.0) | 27 (32.9) | |
| Hydroxychloroquine (%) | 36 (75.0) | 66 (80.5) | |
| Ciclosporin (%) | 4 (8.3) | 9 (11.0) | |
| methotrexate (%) | 2 (4.2) | 10 (12.2) | |
| Mycophenolate mofetil (%) | 6 (12.5) | 8 (9.7) | |
| Oral anticoagulant (%) | 3 (6.3) | 4 (4.9) | |
| Aspirin (%) | 9 (18.8) | 9 (11.0) | |
All included SLE patients were detected positive ANA at least one time to satisfy 2019 EULAR/ACR SLE classification criteria. While SLE blood samples collecting, ANA of some SLE patients may turn negative. SD, standard deviation; LAC, lupus anticoagulant; APTT, activated partial thromboplastin time; PT, prothrombin time; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ANA, anti-nuclear antibody; Anti-dsDNA, anti-double strand DNA; Anti-β2GPI, anti-β2 glycoprotein I; ACL-IgG, anticardiolipin antibody-IgG; ACL-IgM, anticardiolipin antibody-IgM; C3, complement 3; C4, complement 4.